Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Developmental screening at 18 months using the Nipissing District Developmental Screen.

Paediatrics & child health·2025
Same author

Engineered protein inhibitors for precise targeting of matrix metalloproteinases.

Trends in biochemical sciences·2025
Same author

ProBASS-a language model with sequence and structural features for predicting the effect of mutations on binding affinity.

Bioinformatics (Oxford, England)·2025
Same author

Proximal Co-Translation Facilitates Detection of Weak Protein-Protein Interactions.

International journal of molecular sciences·2024
Same author

Engineered TIMP2 with narrow MMP-9 specificity is an effective inhibitor of invasion and proliferation of triple-negative breast cancer cells.

The Journal of biological chemistry·2024
Same author

Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension.

Biomolecules·2024

Related Experiment Video

Updated: Jan 13, 2026

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.9K

Engineered N-TIMP2 Variant Specifically Targeting MMP-9 Exhibits Potent Anti-Glioblastoma Activity.

Mark Feldman1, Naama Rotenberg1, Julia M Shifman1

  • 1Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel.

Biomolecules
|October 29, 2025
PubMed
Summary
This summary is machine-generated.

An engineered N-TIMP2 variant (REY) effectively targets matrix metalloproteinase-9 (MMP-9), inhibiting glioblastoma (GB) cell invasion and spread. This highly specific inhibitor shows promise as a novel therapy for aggressive brain cancer.

Keywords:
MMP inhibitorsglioblastomamatrix metalloproteinase 9 (MMP-9)protein engineeringtissue inhibitor of matrix metalloproteinase 2 (TIMP-2)

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

Related Experiment Videos

Last Updated: Jan 13, 2026

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

Area of Science:

  • Oncology
  • Biochemistry
  • Molecular Biology

Background:

  • Glioblastoma (GB) is an aggressive brain cancer with high recurrence rates due to invasive tumor cells.
  • Matrix metalloproteinase-9 (MMP-9) is crucial for GB progression, invasiveness, and poor prognosis.
  • Targeting MMP-9 presents a potential therapeutic strategy for glioblastoma.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of an engineered N-TIMP2 variant (REY) as an MMP-9 inhibitor.
  • To compare the performance of the engineered REY variant against wild-type N-TIMP2.
  • To assess the therapeutic potential of REY for glioblastoma treatment.

Main Methods:

  • In vitro assays using adult glioblastoma U251 and normal Vero cells.
  • Evaluation of colony formation, cell invasion, and spheroid spreading.
  • Assessment of cytotoxicity and specificity for MMP-9.

Main Results:

  • REY significantly inhibited glioblastoma cell colony formation and invasion at nanomolar concentrations.
  • REY markedly reduced spheroid spreading, indicating reduced invasiveness.
  • The engineered REY variant demonstrated high specificity for MMP-9, outperforming wild-type N-TIMP2 and showing no cytotoxicity to healthy cells.

Conclusions:

  • MMP-9 is a viable therapeutic target for glioblastoma.
  • The engineered N-TIMP2 variant (REY) is a potent and selective MMP-9 inhibitor.
  • REY shows significant therapeutic potential for glioblastoma treatment with a favorable safety profile.